{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:17:51Z","timestamp":1790363871785,"version":"4.1.0"},"reference-count":79,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T00:00:00Z","timestamp":1512604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Eisai Singapore"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1111\/ane.12879","type":"journal-article","created":{"date-parts":[[2017,12,7]],"date-time":"2017-12-07T09:52:55Z","timestamp":1512640375000},"page":"378-391","source":"Crossref","is-referenced-by-count":66,"title":["Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings"],"prefix":"10.1155","volume":"137","author":[{"given":"J.-J.","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Neurology; National Cheng Kung University Hospital and School of Medicine; National Cheng Kung University; Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology; Chang Gung Memorial Hospital; Chang Gung University; Taoyuan City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics; Faculty of Medicine; Prince of Wales Hospital; Hong Kong Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Desudchit","sequence":"additional","affiliation":[{"name":"Department of Paediatrics; King Chulalongkorn Memorial Hospital; Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tiamkao","sequence":"additional","affiliation":[{"name":"Integrated Epilepsy Research Group; Department of Medicine; Faculty of Medicine; Khon Kaen University; Khon Kaen Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-S.","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Neurology; Department of Medicine; Faculty of Medicine; University of Malaya; Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-4021","authenticated-orcid":false,"given":"A.","family":"Dash","sequence":"additional","affiliation":[{"name":"Eisai Singapore Pte. Ltd.; Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,7]]},"reference":[{"key":"10.1111\/ane.12879-BIB0001|ane12879-cit-0001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12879-BIB0002|ane12879-cit-0002","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12879-BIB0003|ane12879-cit-0003","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.phrs.2016.03.016","article-title":"The challenges of treating epilepsy with 25 antiepileptic drugs","volume":"107","author":"Santulli","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1111\/ane.12879-BIB0004|ane12879-cit-0004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11910-016-0678-x","article-title":"Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide","volume":"16","author":"Brodie","year":"2016","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1111\/ane.12879-BIB0005|ane12879-cit-0005","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"issue":"Suppl. 1","key":"10.1111\/ane.12879-BIB0006|ane12879-cit-0006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/epi.12494","article-title":"Medical management of refractory epilepsy-practical treatment with novel antiepileptic drugs","volume":"55","author":"Ben-Menachem","year":"2014","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.1111\/ane.12879-BIB0007|ane12879-cit-0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2009.02238.x","article-title":"Rational polytherapy","volume":"50","author":"French","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0008|ane12879-cit-0008","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/epi.13328","article-title":"Synergism of perampanel and zonisamide in the rat amygdala kindling model of temporal lobe epilepsy","volume":"57","author":"Russmann","year":"2016","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0009|ane12879-cit-0009","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.seizure.2014.06.001","article-title":"Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model","volume":"23","author":"Wu","year":"2014","journal-title":"Seizure"},{"key":"10.1111\/ane.12879-BIB0010|ane12879-cit-0010","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on?","volume":"9","author":"Kwan","year":"2000","journal-title":"Seizure"},{"key":"10.1111\/ane.12879-BIB0011|ane12879-cit-0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2015.09.002","article-title":"Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: impact of mechanism of action and pharmacokinetics on clinical outcomes","volume":"117","author":"Kwan","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12879-BIB0012|ane12879-cit-0012","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"issue":"Suppl 10","key":"10.1111\/ane.12879-BIB0013|ane12879-cit-0013","first-page":"65","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment to carbamazepine in patients with partial-onset seizures","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1111\/ane.12879-BIB0014|ane12879-cit-0014","first-page":"421","article-title":"A post-hoc exploratory analysis of the effect of eslicarbazepine acetate as adjunctive treatment in adult patients with partial-onset seizures refractory to carbamazepine","volume":"13","author":"Gil-Nagel","year":"2013","journal-title":"Epilepsy Curr"},{"key":"10.1111\/ane.12879-BIB0015|ane12879-cit-0015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1111\/ane.12879-BIB0016|ane12879-cit-0016","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12879-BIB0017|ane12879-cit-0017","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/epi.13857","article-title":"Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States","volume":"58","author":"Faught","year":"2017","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0018|ane12879-cit-0018","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0019|ane12879-cit-0019","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/ane.12879-BIB0020|ane12879-cit-0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0021|ane12879-cit-0021","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1111\/ane.12879-BIB0022|ane12879-cit-0022","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1111\/ane.12879-BIB0023|ane12879-cit-0023","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12879-BIB0024|ane12879-cit-0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/1568026053386999","article-title":"AMPA receptor antagonists as potential anticonvulsant drugs","volume":"5","author":"Sarro","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"10.1111\/ane.12879-BIB0025|ane12879-cit-0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","article-title":"Revisiting AMPA receptors as an antiepileptic drug target","volume":"11","author":"Rogawski","year":"2011","journal-title":"Epilepsy Curr"},{"key":"10.1111\/ane.12879-BIB0026|ane12879-cit-0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1111\/ane.12879-BIB0027|ane12879-cit-0027","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6\u00a0Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12879-BIB0028|ane12879-cit-0028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ane.12098","article-title":"Development of perampanel in epilepsy","volume":"197","author":"Satlin","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1111\/ane.12879-BIB0029|ane12879-cit-0029","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/epi.12240","article-title":"Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures","volume":"54","author":"Gidal","year":"2013","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0030|ane12879-cit-0030","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1517\/17425255.2015.1061504","article-title":"Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation","volume":"11","author":"Schulze-Bonhage","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/ane.12879-BIB0031|ane12879-cit-0031","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0032|ane12879-cit-0032","unstructured":"Fycompa prescribing information 2014 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202834lbl.pdf"},{"key":"10.1111\/ane.12879-BIB0033|ane12879-cit-0033","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/ane.12103","article-title":"Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures","volume":"197","author":"Ko","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1111\/ane.12879-BIB0034|ane12879-cit-0034","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/epi.12765","article-title":"Prevention of generalized tonic-clonic seizures in refractory focal epilepsy: a meta-analysis","volume":"55","author":"Hemery","year":"2014","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0035|ane12879-cit-0035","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/epi.12643","article-title":"Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307","volume":"55","author":"Krauss","year":"2014","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0036|ane12879-cit-0036","unstructured":"Anderson P FDA okays perampanel monotherapy for partial-onset seizures http:\/\/www.medscape.com\/viewarticle\/883519"},{"key":"10.1111\/ane.12879-BIB0037|ane12879-cit-0037","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/epi.13600","article-title":"Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies","volume":"58","author":"Leppik","year":"2017","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0038|ane12879-cit-0038","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0039|ane12879-cit-0039","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpn.2015.02.008","article-title":"Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study","volume":"19","author":"Rosenfeld","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1111\/ane.12879-BIB0040|ane12879-cit-0040","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/epi.13417","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety","volume":"57","author":"Lagae","year":"2016","journal-title":"Epilepsia"},{"issue":"Suppl","key":"10.1111\/ane.12879-BIB0041|ane12879-cit-0041","doi-asserted-by":"crossref","first-page":"P7.008","DOI":"10.1212\/WNL.84.14_supplement.P7.008","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial seizures: efficacy and safety results from study 235 (phase II)","volume":"84","author":"Renfroe","year":"2015","journal-title":"Neurology"},{"key":"10.1111\/ane.12879-BIB0042|ane12879-cit-0042","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/epi.13279","article-title":"Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial","volume":"57","author":"Meador","year":"2016","journal-title":"Epilepsia"},{"issue":"Suppl","key":"10.1111\/ane.12879-BIB0043|ane12879-cit-0043","doi-asserted-by":"crossref","first-page":"P1.252","DOI":"10.1212\/WNL.84.14_supplement.P1.252","article-title":"Effect of adjunctive perampanel on growth and development in adolescents with inadequately controlled partial seizures","volume":"84","author":"Pina-Garza","year":"2015","journal-title":"Neurology"},{"key":"10.1111\/ane.12879-BIB0044|ane12879-cit-0044","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.eplepsyres.2014.11.015","article-title":"Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials","volume":"110","author":"Leppik","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12879-BIB0045|ane12879-cit-0045","unstructured":"Neuray C Zimmermann G Villanueva V Perampanel use in older people with epilepsy: pooled data from European observational studies 2017"},{"key":"10.1111\/ane.12879-BIB0046|ane12879-cit-0046","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1111\/epi.13019","article-title":"Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures","volume":"56","author":"Vazquez","year":"2015","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0047|ane12879-cit-0047","unstructured":"Perampanel (Fycompa) Summary of product characteristics http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002434\/WC500130815.pdf"},{"key":"10.1111\/ane.12879-BIB0048|ane12879-cit-0048","unstructured":"Tsai J-J Wu YL Gulhane M Dash A Dhadda S Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures in Asian patients: a subanalysis of pooled phase III study data 2014"},{"key":"10.1111\/ane.12879-BIB0049|ane12879-cit-0049","article-title":"Efficacy, safety, and tolerability of perampanel in Asian populations","author":"Tsai","year":"2018","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0050|ane12879-cit-0050","unstructured":"Nishida T Kaneko S Inoue Y Lee SK Saeki K Ishikawa K A randomized double-blind, placebo-controlled study to evaluate the efficacy and safety of perampanel as adjunctive therapy in patients with refractory partial-onset seizures from the Asia-Pacific region 2015"},{"key":"10.1111\/ane.12879-BIB0051|ane12879-cit-0051","doi-asserted-by":"crossref","first-page":"74","DOI":"10.12809\/hkmj166027","article-title":"Subcommittee on the Consensus Statement of The Hong Kong Epilepsy Society. An update of the Hong Kong Epilepsy Guideline: consensus statement on the use of antiepileptic drugs in Hong Kong","volume":"23","author":"Fong","year":"2017","journal-title":"Hong Kong Med J"},{"key":"10.1111\/ane.12879-BIB0052|ane12879-cit-0052","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ane.12558","article-title":"Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience","volume":"134","author":"Juhl","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12879-BIB0053|ane12879-cit-0053","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yebeh.2015.11.002","article-title":"Prospective audit with adjunctive perampanel: preliminary observations in focal epilepsy","volume":"54","author":"Brodie","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.12879-BIB0054|ane12879-cit-0054","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.eplepsyres.2014.03.015","article-title":"A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria","volume":"108","author":"Steinhoff","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12879-BIB0055|ane12879-cit-0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2015.10.017","article-title":"Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study","volume":"34","author":"Shah","year":"2016","journal-title":"Seizure"},{"key":"10.1111\/ane.12879-BIB0056|ane12879-cit-0056","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12\u00a0months in a real-world setting: the FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12879-BIB0057|ane12879-cit-0057","first-page":"437","article-title":"Perampanel: an audit of clinical experience using the epilepsy electronic patient record","volume":"109","author":"Ryan","year":"2016","journal-title":"Ir Med J"},{"key":"10.1111\/ane.12879-BIB0058|ane12879-cit-0058","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yebeh.2017.04.006","article-title":"Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center","volume":"73","author":"Wehner","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.12879-BIB0059|ane12879-cit-0059","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eplepsyres.2013.05.002","article-title":"Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation","volume":"106","author":"Novy","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12879-BIB0060|ane12879-cit-0060","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1212\/WNL.0000000000001052","article-title":"DRESS associated with perampanel administration in a child with drug-resistant epilepsy","volume":"83","author":"Shimabukuro","year":"2014","journal-title":"Neurology"},{"key":"10.1111\/ane.12879-BIB0061|ane12879-cit-0061","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0035-1546276","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences","volume":"46","author":"Bir\u00f3","year":"2015","journal-title":"Neuropediatrics"},{"key":"10.1111\/ane.12879-BIB0062|ane12879-cit-0062","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eplepsyres.2016.08.021","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies - An Italian observational multicenter study","volume":"127","author":"Liso","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1111\/ane.12879-BIB0063|ane12879-cit-0063","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/dmcn.13362","article-title":"Tolerability and efficacy of perampanel in children with refractory epilepsy","volume":"59","author":"Heyman","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1111\/ane.12879-BIB0064|ane12879-cit-0064","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0883073817709195","article-title":"Clinical experience with perampanel for refractory pediatric epilepsy in one Canadian center","volume":"32","author":"Datta","year":"2017","journal-title":"J Child Neurol"},{"key":"10.1111\/ane.12879-BIB0065|ane12879-cit-0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.seizure.2016.11.012","article-title":"Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies - A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center","volume":"45","author":"Kurth","year":"2017","journal-title":"Seizure"},{"key":"10.1111\/ane.12879-BIB0066|ane12879-cit-0066","unstructured":"Gil-Nagel A Burd S Toledo M A retrospective, multicenter study to investigate dosage, efficacy, and safety of perampanel given as monotherapy in routine clinical care in people with epilepsy 2016"},{"issue":"Suppl","key":"10.1111\/ane.12879-BIB0067|ane12879-cit-0067","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/j.1528-1157.1997.tb04598.x","article-title":"Pharmacologic advantages of antiepileptic drug monotherapy","volume":"38","author":"Perucca","year":"1997","journal-title":"Epilepsia"},{"key":"10.1111\/ane.12879-BIB0068|ane12879-cit-0068","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"10.1111\/ane.12879-BIB0069|ane12879-cit-0069","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yebeh.2016.05.007","article-title":"Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: a single-center postmarketing study","volume":"61","author":"Singh","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.12879-BIB0070|ane12879-cit-0070","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14656566.2017.1328499","article-title":"Anticonvulsant drugs for generalized tonic-clonic epilepsy","volume":"18","author":"Coppola","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"S2","key":"10.1111\/ane.12879-BIB0071|ane12879-cit-0071","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1684\/epd.2016.0861","article-title":"Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials","volume":"18","author":"Michelucci","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1111\/ane.12879-BIB0072|ane12879-cit-0072","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.yebeh.2016.06.041","article-title":"Efficacy and tolerability of perampanel in ten patients with Lafora disease","volume":"62","author":"Goldsmith","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.12879-BIB0073|ane12879-cit-0073","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ebcr.2014.09.003","article-title":"Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel","volume":"2","author":"Dirani","year":"2014","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1111\/ane.12879-BIB0074|ane12879-cit-0074","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ebcr.2013.07.003","article-title":"Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease)","volume":"1","author":"Schorlemmer","year":"2013","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1111\/ane.12879-BIB0075|ane12879-cit-0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ebcr.2016.05.001","article-title":"Add-on perampanel in Lance-Adams syndrome","volume":"6","author":"Steinhoff","year":"2016","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1111\/ane.12879-BIB0076|ane12879-cit-0076","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ebcr.2015.06.007","article-title":"Use of perampanel in one case of super-refractory hypoxic myoclonic status: case report","volume":"4","author":"Santamarina","year":"2015","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1111\/ane.12879-BIB0077|ane12879-cit-0077","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.yebeh.2015.01.036","article-title":"Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus","volume":"45","author":"Redecker","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.12879-BIB0078|ane12879-cit-0078","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.yebeh.2015.04.005","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit","volume":"49","author":"Rohracher","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1111\/ane.12879-BIB0079|ane12879-cit-0079","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/epi.13008","article-title":"Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA\/kainate receptor antagonist BGG492: clear PK\/PD relationship","volume":"56","author":"Kasteleijn-Nolst Trenit\u00e9","year":"2015","journal-title":"Epilepsia"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12879","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12879\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T14:18:06Z","timestamp":1719670686000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,7]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12879","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,7]]}}}